Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

V.M. Macaulay; M.R. Middleton; A.S. Protheroe; A. Tolcher; V. Dieras; C. Sessa; R. Bahleda; J.-Y. Blay; P. LoRusso; D. Mery-Mignard; J.-C. Soria

doi:10.1093/annonc/mds511

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mds511 ◽

2013 ◽

Vol 24 (3) ◽

pp. 784-791 ◽

Cited By ~ 32

Author(s):

V.M. Macaulay ◽

M.R. Middleton ◽

A.S. Protheroe ◽

A. Tolcher ◽

V. Dieras ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor ◽

Humanized Monoclonal Antibody

Download Full-text

A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-016-3041-7 ◽

2016 ◽

Vol 77 (6) ◽

pp. 1253-1262 ◽

Cited By ~ 4

Author(s):

Toshihiko Doi ◽

Kohei Shitara ◽

Takashi Kojima ◽

Takayuki Yoshino ◽

Aruna Dontabhaktuni ◽

...

Keyword(s):

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Japanese Patients ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor ◽

Receptor Inhibitor

Download Full-text

Abstract B123: A phase I study of R1507, a human monoclonal antibody IGF‐1R (insulin‐like growth factor receptor) antagonist in patients with advanced solid tumors

10.1158/1535-7163.targ-09-b123 ◽

2009 ◽

Author(s):

Lia Gore ◽

Joseph Aisner ◽

Razelle Kurzrock ◽

Cinara D. McCarthy ◽

Erica Winter ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Receptor Antagonist ◽

Solid Tumors ◽

Phase I Study ◽

Human Monoclonal Antibody ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor

Download Full-text

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mdv144 ◽

2015 ◽

Vol 26 (6) ◽

pp. 1230-1237 ◽

Cited By ~ 42

Author(s):

E.G. Chiorean ◽

H.I. Hurwitz ◽

R.B. Cohen ◽

J.D. Schwartz ◽

R.P. Dalal ◽

...

Keyword(s):

Monoclonal Antibody ◽

Vascular Endothelial Growth Factor ◽

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Advanced Solid Tumors ◽

Endothelial Growth Factor

Download Full-text

A phase I study of MK-0646, a humanized monoclonal antibody against the insulin-like growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3520 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3520-3520 ◽

Cited By ~ 26

Author(s):

M. Hidalgo ◽

M. Tirado Gomez ◽

N. Lewis ◽

J. L. Vuky ◽

G. Taylor ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Solid Tumor ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumor ◽

Tumor Patients ◽

Humanized Monoclonal Antibody

Download Full-text

A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-3220 ◽

2010 ◽

Vol 16 (8) ◽

pp. 2458-2465 ◽

Cited By ~ 123

Author(s):

Razelle Kurzrock ◽

Amita Patnaik ◽

Joseph Aisner ◽

Terri Warren ◽

Stephen Leong ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Receptor Antagonist ◽

Solid Tumors ◽

Phase I Study ◽

Human Monoclonal Antibody ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor ◽

Factor I

Download Full-text

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-014-2389-9 ◽

2014 ◽

Vol 73 (3) ◽

pp. 595-604 ◽

Cited By ~ 42

Author(s):

E. Gabriela Chiorean ◽

Christopher Sweeney ◽

Hagop Youssoufian ◽

Amy Qin ◽

Aruna Dontabhaktuni ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Platelet Derived Growth Factor ◽

Advanced Solid Tumors ◽

Receptor Alpha ◽

Factor Receptor Alpha

Download Full-text

Faculty Opinions recommendation of Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14346.471799 ◽

2006 ◽

Author(s):

Jeffrey Evans

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Growth Factor Receptor ◽

Advanced Solid Tumors ◽

Irreversible Inhibitor ◽

Epidermal Growth

Download Full-text

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-10-3336 ◽

2011 ◽

Vol 17 (19) ◽

pp. 6304-6312 ◽

Cited By ~ 78

Author(s):

Francesco Atzori ◽

Josep Tabernero ◽

Andrés Cervantes ◽

Ludmila Prudkin ◽

Jordi Andreu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Growth Factor ◽

Phase I ◽

Solid Tumors ◽

Advanced Solid Tumors ◽

Insulin Like Growth Factor ◽

Pharmacodynamic Study ◽

Receptor Monoclonal Antibody

Download Full-text

A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.3537 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 3537-3537 ◽

Cited By ~ 18

Author(s):

M. N. Saleh ◽

I. Percent ◽

T. E. Wood ◽

J. Posey ◽

J. Shah ◽

...

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Death Receptor ◽

Advanced Solid Tumors ◽

Death Receptor 5 ◽

Humanized Monoclonal Antibody ◽

Antibody Targeting

Download Full-text

A phase I study of sonepcizumab (S), a humanized monoclonal antibody to sphingosine-1-phosphate (S1P), in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.2560 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 2560-2560 ◽

Cited By ~ 8

Author(s):

M. S. Gordon ◽

R. Just ◽

L. S. Rosen ◽

A. Dorr

Keyword(s):

Monoclonal Antibody ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Advanced Solid Tumors ◽

Humanized Monoclonal Antibody ◽

Sphingosine 1 Phosphate

Download Full-text